Is GRI Bio, Inc. (GRI) a Buy, Sell, or Hold?
GRI Bio, Inc.
NASDAQ:GRI
$1.62 USD
$0.05 (3.18%)
- Volume
- 33.32K
- Average Volume
- 67.18K
- Market Capitalization
- $145.53K
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $80.36
- Year Low
- $1.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.21
| Source | Headline |
|---|---|
|
Banner Bank Releases New Corporate Responsibility Report
Today, Banner Bank released its 2025 Corporate Responsibility Report. The report identifies ongoing practices and recent accomplishments that contribute to crea gurufocus.com - 2026-07-14 14:00:00 |
|
Asbury Automotive Group Named in TIME America's Best Companies 2026 List
Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S, is proud to be recognized on TIME's list of A gurufocus.com - 2026-07-09 09:00:00 |
|
Luxshare Precision Releases 2025 Sustainability Report
Luxshare Precision Releases 2025 Sustainability Report PR Newswire NEW YORK, June 23, 2026 gurufocus.com - 2026-06-23 04:00:00 |
|
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TOWARD 2030 GOALS
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TO gurufocus.com - 2026-06-22 12:00:00 |
|
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity globenewswire.com - 2026-06-18 08:31:00 |
|
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U. S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that the U. globenewswire.com - 2026-06-18 08:31:00 |
|
The Toro Company Publishes 2025 Global Sustainability Impact Report
The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today released its fiscal 2025 Sustainability Impact Report. gurufocus.com - 2026-06-10 09:00:00 |
|
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. globenewswire.com - 2026-05-18 09:15:00 |
|
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A. globenewswire.com - 2026-05-18 09:15:00 |
|
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination globenewswire.com - 2026-05-14 08:35:00 |
